Oxathiazin_dioxide for treating, preventing, inhibiting or reducing cytokine release
A method of preventing, inhibiting or reducing cytokine release and the incidence of a cytokine release syndrome (CRS) or a cytokine storm in a subject with certain oxathiazin-like compounds and/or related compounds.
1 . A method of inhibiting, or reducing an increase in blood levels of one or more cytokines in a subject in need thereof that has cancer, and is undergoing T-cell engaging therapy, chimeric antigen receptor-expressing T-cell (CAR T-cell) cancer therapy, or antibody therapy, the method comprising the step of administering a composition comprising compound 2250
a pharmaceutically acceptable salt, hydrate, ester, prodrug, or solvate thereof to the subject, and thereby inhibiting or reducing release of at least one cytokine in said subject.
2 . The method of claim 1 , wherein the at least one cytokine is IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-α, IFN-γ, G-CSF, or TNF-α.
3 . The method of claim 1 , wherein the subject is undergoing T-cell engaging therapy.
4 . The method of claim 1 , wherein the subject is undergoing chimeric antigen receptor-expressing T-cell (CAR T-cell) cancer therapy, or bispecific antibody therapy.
5 . The method of claim 1 , wherein administration of said composition occurs prior to, concurrent with, or following CAR T-cell therapy, antibody therapy or bispecific antibody therapy.
6 . The method of claim 1 , wherein the composition is administered 12 to 96 hours prior to initiation of CAR T-cell therapy or bispecific antibody therapy.
7 . The method of claim 1 , further comprising monitoring the subject for onset of fever as a clinical sign of impending CRS or cytokine storm in patients receiving T cell-engaging therapy and administering compound 2250 within 24 hours of the onset of fever.
8 . The method of claim 1 , further comprising monitoring the subject for one or more biomarkers indicative of impending CRS or cytokine storm in patients receiving T cell-engaging therapies and administering compound 2250 within 24 hours of detection of the one or more biomarkers.
9 . The method of claim 8 , wherein the one or more biomarkers indicative of impending CRS is an increased serum, blood or tissue level of one or more of IL-1β, IL-1RA, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IP-10, IFN-α, IFN-γ, G-CSF, and TNF-α.
10 . The method of claim 1 , wherein the composition is administered at least biweekly for 4 to 8 weeks.
11 . The method of claim 1 , wherein said method does not reduce efficacy of said CAR T-cell cancer therapy or antibody therapy.
12 . The method of claim 1 , wherein the subject further suffers from one or more disease conditions selected from at least one of cachexia, septic shock syndrome, a chronic inflammatory response, traumatic brain injury, a neuromyelitis optica spectrum disorder (NMSOD), cerebral cytokine storm, graft versus host disease (GVHD), autoimmune diseases, multiple sclerosis, acute pancreatitis, or hepatitis.
13 . The method of claim 1 , wherein the subject is treated with anti-CD19 Chimeric Antigen Receptor (CAR) T cells.
14 . A method of treating, inhibiting or reducing the incidence of a cytokine release syndrome (CRS) or a cytokine storm in a subject in need thereof that has cancer and is undergoing T-cell engaging therapy, chimeric antigen receptor-expressing T-cell (CAR T-cell) cancer therapy, or antibody therapy, the method comprising the step of administering a composition comprising compound 2250
a pharmaceutically acceptable salt, hydrate, ester, prodrug, or solvate thereof, or a combination thereof to the subject in need thereof that has cancer and is at risk of CRS or cytokine storm due to T-cell engaging therapy, chimeric antigen receptor-expressing T-cell (CAR T-cell) cancer therapy, or antibody therapy.
15 . The method of claim 14 , wherein the subject is experiencing CRS or cytokine storm CRS or cytokine storm.
16 . The method of claim 14 , wherein said subject is undergoing CAR T-cell cancer therapy or antibody therapy and said method does not reduce the efficacy of said CAR T-cell cancer therapy, antibody therapy or bispecific antibody therapy.